MAM
Ipsos buys into behavioural brilliance with The BVA Family acquisition
MUMBAI : Ipsos has officially acquired The BVA Family, ticking off all regulatory boxes and marking a major move to bulk up its capabilities in customer experience, behavioural science, and public sector research. The deal, finalised after consultations with employee reps in France and competition greenlights, adds muscle not just at home, but also in the UK and Italy.
With this acquisition, Ipsos gains a sharp edge in point-of-sale behaviour analysis and government services research — areas where BVA has carved a name for itself. Of particular note is BVA’s behavioural science-led approach and its globally respected packaging research arm, Prs in Vivo.
Ipsos CEO Ben Page stated, “We are delighted to welcome The BVA Family teams to Ipsos. They now benefit from our global infrastructure, and the opportunities our scale brings them, while our clients will have access to new, innovative solutions. With our strong cultural fit and complementary set of services, we are poised to deliver even greater value to the businesses and organizations we serve.”
The BVA Family chairmen Gerard Lopez and Pascal Gaudin added, “We are pleased to join forces with Ipsos, one of the world leaders in market research. This partnership allows us to leverage its international presence and solid competencies, significantly enhancing our capabilities to provide cutting-edge analysis and understanding of society and markets to our clients.” Ipsos France will now operate under the name Ipsos Bva, while the teams in Italy will use the name Ipsos Doxa. In the UK, BDRC will operate under the Ipsos brand.
The acquisition allows Ipsos to scale up BVA’s methodologies and deploy them across its wider international footprint, signalling a serious intent to lead in the evolving landscape of human-centric research.
(If you are an Anime fan and love Anime like Demon Slayer, Spy X Family, Hunter X Hunter, Tokyo Revengers, Dan Da Dan and Slime, Buy your favourite Anime merchandise on AnimeOriginals.com.)
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
